Shares of AC Immune (Nasdaq: ACIU) rose nearly 50% yesterday, and were up a further 15% at $8.43 pre-market today, after the Swiss biotech released positive data for its investigational Alzheimer’s vaccine.
AC Immune announced positive interim results from its ongoing Phase Ib/IIa clinical trial evaluating its first-in-class anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer’s disease (AD). ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD, achieving antibody levels several orders of magnitude higher than pre-vaccination levels. No clinically relevant adverse events were observed.
AC Immune and strategic partner Janssen Pharmaceuticals, a unit of US healthcare giant Johnson & Johnson (NYSE: JNJ), believe these interim findings from the first two dosing groups support plans to advance the development of ACI-35.030 for the treatment of AD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze